ArticleFuture neurology2010
Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions.
Article in Future neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Planning for the future following receipt of Alzheimer's disease risk estimate among Latinos in New York City.Journal of Alzheimer's disease : JAD · 2025Article
- A mixed-methods study of cultural beliefs about dementia and genetic testing among Mexicans and Mexican-Americans at-risk for autosomal dominant Alzheimer's disease.Journal of genetic counseling · 2019Article
- Normal-But-Low Serum Folate Levels and the Risks for Cognitive Impairment.Psychiatry investigation · 2019Article
- Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.Alzheimer's research & therapy · 2019Article
- From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting.Alzheimer's & dementia (New York, N. Y.) · 2018Review
- Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals.Journal of Alzheimer's disease : JAD · 2018Article
- Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.Alzheimer's research & therapy · 2017Article
- Kinetics and Molecular Docking Studies of 6-Formyl Umbelliferone Isolated from Angelica decursiva as an Inhibitor of Cholinesterase and BACE1.Molecules (Basel, Switzerland) · 2017Article
- Public beliefs and knowledge about risk and protective factors for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2014Article
- Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study.PloS one · 2014Article
- A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.Progress in neurobiology · 2013Review
- Impact of genetic risk assessment on nutrition-related lifestyle behaviours.The Proceedings of the Nutrition Society · 2013Review
- Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease.NeuroImage. Clinical · 2013Review
- Differences between African American and White research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease.Journal of genetic counseling · 2011Article
- Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.Neurodegenerative disease managementArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
With Alzheimer's disease increasing in prevalence and public awareness, more people are becoming interested in learning their chances of developing this condition. Disclosing Alzheimer's disease risk has been discouraged because of the limited predictive value of available tests, lack of prevention and treatment options, and concerns regarding potential psychological and social harms. However, challenges to this status quo include the availability of direct-to-consumer health risk information (e.g., genetic susceptibility tests), as well as a growing literature suggesting that people seeking risk information for Alzheimer's disease through formal education and counseling protocols generally find it useful and do not experience adverse effects. This paper reviews current and potential methods of risk assessment for Alzheimer's disease, discusses the process and impact of disclosing risk to interested patients and consumers, and considers the practical and ethical challenges in this emerging area. Anticipated future directions are addressed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.